Dongxia Gao

List of Publications by Year
in descending order

26 papers	1,388 citations	623734 14 h-index	580821 25 g-index
26 all docs	26 docs citations	26 times ranked	3020 citing authors

#	Article	IF	Citations
1	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell Metabolism, 2015, 22, 577-589.	16.2	430
2	An international study to increase concordance in Ki67 scoring. Modern Pathology, 2015, 28, 778-786.	5.5	195
3	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. Npj Breast Cancer, 2016, 2, 16014.	5.2	109
4	Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. Cancer Immunology Research, 2019, 7, 1064-1078.	3.4	104
5	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. OncoImmunology, 2020, 9, 1747340.	4.6	101
6	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Modern Pathology, 2019, 32, 1772-1785.	5.5	61
7	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nature Communications, 2022, 13, 896.	12.8	46
8	High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. Clinical Cancer Research, 2017, 23, 946-953.	7.0	45
9	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer, 2017, 17, 618.	2.6	42
10	TIM-3 expression in breast cancer. OncoImmunology, 2018, 7, e1502128.	4.6	42
11	Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer. JAMA Oncology, 2017, 3, e172085.	7.1	37
12	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. Breast Cancer Research and Treatment, 2016, 155, 483-490.	2.5	30
13	Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. Modern Pathology, 2020, 33, 1753-1763.	5.5	25
14	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Research and Treatment, 2021, 185, 557-566.	2.5	19
15	Phospho-Ser784-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. Cell Reports, 2020, 31, 107745.	6.4	17
16	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Reports, 2021, 37, 109817.	6.4	14
17	Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. Histopathology, 2017, 70, 185-194.	2.9	13
18	Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. Breast Cancer Research and Treatment, 2018, 168, 107-115.	2.5	12

#	Article	IF	Citations
19	Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer. Cancers, 2021, 13, 5769.	3.7	12
20	Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. International Journal of Cancer, 2019, 144, 2578-2586.	5.1	9
21	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. OncoImmunology, 2021, 10, 1924492.	4.6	8
22	Stroma vs epithelium–enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. International Journal of Cancer, 2021, 148, 481-491.	5.1	7
23	Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints. Cancers, 2021, 13, 1022.	3.7	6
24	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. Npj Breast Cancer, 2021, 7, 114.	5.2	3
25	Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. Clinical Cancer Research, 2021, 27, 6570-6579.	7.0	1
26	Abstract 5271: Correlative analysis of RNA biomarkers for adjuvant capecitabine benefit in the CIBOMA/2004-01phase III clinical trial of triple negative breast cancer patients. Cancer Research, 2022, 82, 5271-5271.	0.9	0